PMID- 30886803
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231006
IS  - 2198-3844 (Print)
IS  - 2198-3844 (Electronic)
IS  - 2198-3844 (Linking)
VI  - 6
IP  - 5
DP  - 2019 Mar 6
TI  - Synergistic MicroRNA Therapy in Liver Fibrotic Rat Using MRI-Visible Nanocarrier 
      Targeting Hepatic Stellate Cells.
PG  - 1801809
LID - 10.1002/advs.201801809 [doi]
LID - 1801809
AB  - Liver fibrosis, as one of the leading causes of liver-related morbidity and 
      mortality, has no Food and Drug Administration (FDA)-approved antifibrotic 
      therapy yet. Although microRNA-29b (miRNA-29b) and microRNA-122 (miRNA-122) have 
      great potential in treating liver fibrosis via regulating profibrotic genes in 
      hepatic stellate cells (HSCs), it is still a challenge to achieve a HSC-targeted 
      and meanwhile noninvasively trackable delivery of miRNAs in vivo. Herein, a 
      pH-sensitive and vitamin A (VA)-conjugated copolymer VA-polyethylene 
      glycol-polyethyleneimine-poly(N-(N',N'-diisopropylaminoethyl)-co-benzylamino) 
      aspartamide (T-PBP) is synthesized and assembled into superparamagnetic iron 
      oxide (SPIO)-decorated cationic micelle for miRNA delivery. The T-PBP micelle 
      efficiently transports the miRNA-29b and miRNA-122 to HSC in a magnetic resonance 
      imaging-visible manner, resulting in a synergistic antifibrosis effect via 
      downregulating the expression of fibrosis-related genes, including collagen type 
      I alpha 1, alpha-smooth muscle actin, and tissue inhibitor of metalloproteinase 1. 
      Consequently, the HSC-targeted combination therapy with miRNA-29b and miRNA-122 
      demonstrates a prominent antifibrotic efficacy in terms of improving liver 
      function and relieving hepatic fibrosis.
FAU - Wu, Jun
AU  - Wu J
AD  - The Third Affiliated Hospital Sun Yat-sen University Guangzhou 510630 China.
FAU - Huang, Jinsheng
AU  - Huang J
AUID- ORCID: 0000-0002-6371-4532
AD  - PCFM Lab of Ministry of Education School of Materials Science and Engineering Sun 
      Yat-sen University Guangzhou 510275 China.
FAU - Kuang, Sichi
AU  - Kuang S
AD  - The Third Affiliated Hospital Sun Yat-sen University Guangzhou 510630 China.
FAU - Chen, Jingbiao
AU  - Chen J
AD  - The Third Affiliated Hospital Sun Yat-sen University Guangzhou 510630 China.
FAU - Li, Xiaoxia
AU  - Li X
AD  - PCFM Lab of Ministry of Education School of Materials Science and Engineering Sun 
      Yat-sen University Guangzhou 510275 China.
FAU - Chen, Bin
AU  - Chen B
AUID- ORCID: 0000-0002-6869-1843
AD  - Department of Orthopaedics and Traumatology Nanfang Hospital Southern Medical 
      University Guangzhou 510515 China.
FAU - Wang, Jin
AU  - Wang J
AUID- ORCID: 0000-0002-7956-9579
AD  - The Third Affiliated Hospital Sun Yat-sen University Guangzhou 510630 China.
FAU - Cheng, Du
AU  - Cheng D
AUID- ORCID: 0000-0001-5105-7777
AD  - PCFM Lab of Ministry of Education School of Materials Science and Engineering Sun 
      Yat-sen University Guangzhou 510275 China.
FAU - Shuai, Xintao
AU  - Shuai X
AUID- ORCID: 0000-0003-4271-0310
AD  - The Third Affiliated Hospital Sun Yat-sen University Guangzhou 510630 China.
AD  - PCFM Lab of Ministry of Education School of Materials Science and Engineering Sun 
      Yat-sen University Guangzhou 510275 China.
LA  - eng
PT  - Journal Article
DEP - 20190115
PL  - Germany
TA  - Adv Sci (Weinh)
JT  - Advanced science (Weinheim, Baden-Wurttemberg, Germany)
JID - 101664569
PMC - PMC6402399
OTO - NOTNLM
OT  - hepatic stellate cells
OT  - liver fibrosis
OT  - magnetic resonance imaging visibility
OT  - miRNA delivery
OT  - nanomedicine
OT  - synergistic therapy
COIS- The authors declare no conflict of interest.
EDAT- 2019/03/20 06:00
MHDA- 2019/03/20 06:01
PMCR- 2019/01/15
CRDT- 2019/03/20 06:00
PHST- 2018/10/15 00:00 [received]
PHST- 2018/12/10 00:00 [revised]
PHST- 2019/03/20 06:00 [entrez]
PHST- 2019/03/20 06:00 [pubmed]
PHST- 2019/03/20 06:01 [medline]
PHST- 2019/01/15 00:00 [pmc-release]
AID - ADVS951 [pii]
AID - 10.1002/advs.201801809 [doi]
PST - epublish
SO  - Adv Sci (Weinh). 2019 Jan 15;6(5):1801809. doi: 10.1002/advs.201801809. 
      eCollection 2019 Mar 6.